(WGS) GeneDx Holdings - Ratings and Ratios

GeneDx Holdings Corp. (NASDAQ:WGS) is a leading genomics company specializing in genetic testing services. The firm focuses on pediatric and rare disease diagnostics, leveraging advanced technologies such as whole exome and genome sequencing to deliver precise diagnostic solutions. Additionally, it provides data and information services to support clinical decision-making. Headquartered in Stamford, Connecticut, GeneDx is recognized for its comprehensive approach to genetic testing, combining clinical expertise with cutting-edge sequencing technologies. Web URL: https://www.genedx.com

Based on the provided data, the 3-month forecast for WGS indicates potential volatility. Technically, the stock is currently trading above its 20-day SMA (93.93) and 50-day SMA (95.55) but below its 200-day SMA (66.82), suggesting short-term bullish momentum amidst a broader bearish trend. The ATR of 7.83 indicates moderate volatility. Support levels at 99.0, 85.3, 77.5, and 69.0 may act as price floors. Fundamentally, the companys high P/S ratio (10.22) and P/B ratio (12.73) suggest a premium valuation, while the negative RoE (-21.32) raises concerns about profitability. Expect sideways to upward movement in the near term, with potential resistance at higher SMA levels.